Biolegend, 796406, Biotinylated Recombinant Human TNFRSF17-Fc Chimera (carrier-free)

Human TNFRSF17, a type I attached membrane protein of 184 amino acids, possesses a conserved motif of six cysteines in the N-terminal, consistent with the formation of a cysteine repeat motif found in the extracellular domain of TNFRs. Overexpression of TNFRSF17 in 293 cells activates NF-kappa B, Elk-1, the c-Jun N-terminal kinase, and the p38 mitogen-activated protein kinase, after its association with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3. Soluble forms of TACI (TNFRSF13B) and TNFRSF17 bind to BAFF (TNFSFL13B) and APRIL (TNFSFL13A); the interaction of TNFRSF17 to APRIL has higher affinity than the TNFRSF17-BAFF interaction. Analysis of BCMA knockout mice (BCMA−/−) showed no differences in the steady-state frequencies or composition of peripheral B cell subsets (immature, marginal zone, follicular, B1). TNFRSF17 expression is upregulated on PBMCs from mice that develop a Sjogren’s-like syndrome, patients with Sjogren’s syndrome, with rheumatoid arthritis, and on B cells from SLE patients. Patients with multiple myeloma show elevated serum BCMA levels and it correlated with the proportion of plasma cells in bone marrow biopsies and clinical status. Serum BCMA levels is considered a novel biomarker to predict outcomes for multiple myeloma patients.